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GATE-KEEPING BY MEDICAL
RESEARCHER/PRACTITIONERS: A CASE STUDY
The wider Cape Town metropolitan area is home to several 
antiretroviral treatment and vaccine initiatives funded by
NGOs and pharmaceutical companies. All of these entail
collaboration with the Western Cape government (which has
de jure ownership of the clinics). Most of the projects have
strong links with university-based medical researchers, some
of whom also offer medical or related support services to the
projects. Many HIV clinicians are thus simultaneously medical
practitioners and researchers. 
In this world of overlap between service provision and
research interests, patients on antiretroviral treatment are
both beneficiaries and research subjects. They enter a world
entirely controlled by medical practitioner/researchers.
Although the clinics are technically under the control of the
government, decision-making power in effect is ceded to the
largely foreign-funded doctors and researchers who run the
interventions. They decide who can be on the premises, what
research is ‘acceptable’, and who can interview the patients.
This gatekeeper role has serious implications for social
scientists trying to conduct research – as one of my PhD
students discovered to her cost. 
The student, a trained and registered clinical psychologist,
wanted to conduct research into the psychological well-being
and coping strategies of low socio-economic status mothers
on antiretroviral treatment. Her research entailed recruiting 75
HIV-positive mothers and interviewing them when they
started treatment, and then again after 4, 12 and 24 weeks. A
sample of 75 HIV-negative mothers from the community was
to be recruited as the comparison group. The aim of the
research was to explore the challenges to women’s care-giving
and psychological well-being posed by negotiating the
multiple roles of living with HIV, caring for young children and
dealing with the general stressors associated with poverty.
She was particularly interested in drawing out the implications
of these multiple roles for women’s adherence to antiretroviral
therapy.
In addition to interviewing the women, the student stated her
intention to ask the participants for permission to access their
medical files so that she could collect data on CD4 counts,
viral loads, clinical staging and adherence information. She
stressed that this information would only be collected at the
convenience of the clinic. In her research protocol, she
acknowledged that she would need the help of clinic staff in
accessing the files, but argued that this cost was small in
relation to the benefits of her study. She pointed out that she
and her researchers are clinically trained (and registered with
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There is an understandable tension between medical researchers and social scientists when it comes to AIDS-related research
at clinic level. Clinics offering antiretroviral treatment exist primarily to assist patients – but many of them also provide ‘data’
for medical researchers. This may involve a randomised controlled trial, or simply the collection of data on adherence. A social
scientist wishing to access patients to conduct interviews or focus groups thus (inevitably) appears to the HIV clinician as at
best a disruption to an already over-stretched operation, and at worst a potentially confounding factor in his or her own
research. 
Given that the medical practitioner/researchers effectively control the clinics, the temptation to deny social scientists access
to patients must be strong. As discussed below, this was the case with regard to two Cape Town clinics that prevented a clinical
psychologist (working in my research unit) from conducting social science research. Although understandable, such
unaccountable exercise of power denies patients the opportunity to participate in other research projects that may be of
benefit to them (or society) in ways that HIV clinicians do not necessarily appreciate. As such, it violates the principle of
informed consent. It is also problematic in that it restricts the AIDS research agenda to biomedical concerns. This is particularly
worrying with regard to AIDS, where it is widely accepted (by social scientists and HIV clinicians alike) that social and
psychological factors matter a great deal for HIV prevention and treatment interventions. 
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the Health Professions and Social Work Councils) and thus in
a position to provide useful feedback to the clinic on patients
who were deemed to be at risk for poor adherence owing to
their mental health and social difficulties. She also pointed out
that some of the empirical indicators being developed in her
study could potentially become useful tools for the
counsellors associated with the treatment programme to use
in the future should they wish to assess the extent to which a
patient's psychological well-being places them at risk for poor
adherence: ‘More broadly, the research aims to make
recommendations about the kinds of psychosocial services
which can enhance women patients’ quality of life and
psychological well-being, as well as enhancing their adherence
to treatment’ (student research protocol).
The student approached a clinic in a local African township for
permission to invite potential respondents to participate in her
study. The medical practitioner/researchers associated with
the antiretroviral treatment project at the clinic considered her
request – but rejected it. As can be seen from the three
reasons listed below, the fact that the research and treatment
intervention was funded in part through a large pharma-
ceutical company seemed to pose particular problems. 
1. ‘The population is over-researched and your study is not
the primary focus of the research’ (‘the research’ referring,
of course, to the research already being conducted by the
medical doctors/researchers linked to the clinic);
2. ‘None of the (pharmaceutical company ) Exco members are
senior authors of the project’ (i.e. the student’s doctoral
project); and
3. ‘It has not been approved by the same Ethics Committee as
the other (pharmaceutical company ) projects’ (written
response to the student).
The student was then referred to another clinic in a different
African township, but was again turned down by the
gatekeeper committee of medical practitioner/researchers.
This time she was turned down principally because:
1. There were insufficient ‘direct and tangible benefits to the
clinic patients’; 
2. They were concerned about the ‘amount of time’
respondents would have to spend on the study; and
3. They did not ‘feel that the research addresses the needs
which they have as a clinic at this point in time, and only
want to permit research which does so’ (response to the
student).
The student responded to the main research gatekeeper of this
clinic by reiterating that her research could be of potential
direct and immediate benefit to the counsellors who work
with people on antiretroviral treatment as well as to the
patients themselves: ‘Depending on the clinic’s need, feedback
from the research could either be restricted to liaising with the
counselling team, or direct input could also be given to the
other members of the clinic team if relevant and useful.
Whichever approach minimises the negative impact of our
presence on the running of the service, while maximising the
support and benefits, is desirable for me’ (response by the
student).
She never got a reply to this correspondence. She made
several phone calls (all to no effect) and eventually gave up.
Fortunately, a local clinic run by Absolute Return for Kids (ARK)
came to the rescue and let her conduct her research there. The
fact that it was not linked to either a pharmaceutical company
or a major research project no doubt helped …
This story of her rejection by the first two clinics is interesting
in several respects. Firstly, with regard to both clinics she
approached, the medical practitioner/researchers prioritised
their own research interests and used their effective control
over the clinic to prevent other research from taking place. The
blocking of research by the first clinic on the grounds that
only research linked to the pharmaceutical company that was
funding it would be acceptable was breath-taking in its
blatant self-interest.
Secondly, it is clear from the reasons provided by the second
clinic that non-medical interventions were not regarded as
potentially being of value to the patient. This reflects an
uncritical adoption of a strictly biomedical notion of health
promotion which is particularly worrying given the obvious
social and psychological determinants of adherence to
antiretroviral therapy. It also demonstrates a lack of
understanding that even when the ‘benefits’ of social science
research for a particular individual patient are not obvious, the
research may nevertheless inform the development of relevant
future social policies. A narrow application of the requirement
that the research ‘benefits’ the research subject is therefore
necessarily always going to be biased against the social
scientist. 
Thirdly, the story demonstrates a paternalistic approach on the
part of medical practitioner/researchers to who is in the best
position to judge whether a project is, or is not, in the best
interests of the patient. This, in my view, runs counter to the
spirit of the principle of informed consent. Although the
principle of informed consent was designed to ensure that
prospective research subjects have the right to refuse to
participate, it surely also protects these same subjects from
others deciding on their behalf that it is not in their best
interests to participate. The principle should surely be that
research subjects have the right to decide whether they want
– or do not want – to participate. In my experience of
conducting surveys and qualitative in-depth interviews,
research subjects often enjoy being interviewed and having
the opportunity to discuss matters of concern to them (see
also Pahl1). This is, of course, not true for all participants. Some
get irritated by the research process, but they can always
refuse to participate at any point (as is typically – if not always
– pointed out in consent forms). 
Ultimately, it must be up to the potential research participant
to decide whether the risks (which, in social science research,
typically entail little more than the opportunity cost of the
time taken up by the interview) outweigh the benefits. Medical
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practitioner/researchers are not in an appropriately informed
position to make the judgement call. 
SOME ETHICAL CONCERNS
Most research ethics codes are silent on the issue of ensuring
that potential research subjects have the right to choose
whether they do or do not want to participate in research. The
European Group on Ethics in Science and New Technologies2
and the Nuffield Council on Bioethics (UK)3 note that in some
local contexts, it may be appropriate to obtain family- or
community-level agreement before approaching research
subjects (see discussion in NCOB,4 p. 73). However, this is a
concession to local culture – it cannot be used to justify giving
medical practitioner/researchers the right to make decisions
on the behalf of their patients, especially in cases where these
same medical practitioner/researchers are not disinterested
observers.
Before 1947, when the Nuremburg code of ethics for medical
research highlighted the need for informed consent,5 the
prevailing ‘Hippocratic’ approach assumed that medical
researchers and doctors were the only agents capable of
making appropriate judgements about medical research.6
Refusing to allow patients on antiretroviral therapy the
opportunity to make their own decision as to whether they
wish to participate in a psychological study or not amounts to
a reversion to this old paternalistic approach. 
Some attention has been paid to the problem of ‘dual loyalty’
– i.e. when a clinician experiences a role conflict between their
professional duties to a patient and the obligations, expressed
or implied, real or perceived, to the interests of a third party
(see Physicians for Human Rights and University of Cape Town
Health Sciences Faculty7). However, as Singh points out,8 this
problem has yet to be applied to dual loyalty in medical
research – especially when the roles of clinician and researcher
merge: ‘In the practice-research context this translates to the
physician-researcher’s primary interest (duty of care towards
the patient-subject) being undermined by secondary factors
(such as loyalty to the study/sponsor)’ (p. 395). Furthermore,
clinicians may deny social scientists access to ‘their’ patients
not because they are worried about the adverse implications of
the social science research for the patients, but because they
do not want any other research (besides their own) being
conducted on the patients.
Disciplinary differences like this would not matter except for
the fact that medical practitioner/researchers are in a powerful
position to dictate the research agenda largely because they
have access to extraordinarily large budgets to treat and
research their patients. In a very real sense, these medical
practitioner/researchers do indeed control ‘their’
patients/research subjects – and as discussed above, they can
use this power and deny others research access to them.
With about a fifth of the adult population HIV-positive, and
given the government’s reluctance to roll out antiretroviral
therapy with any sense of urgency, there is substantial
pressure (both in terms of resources and emotional energies)
on HIV clinicians. Their irritation with social science research is
therefore in some way understandable. However, as the AIDS
crisis is both a social and health crisis, and given that social
scientists are often better placed than medical practitioners to
understand the social and behavioural context governing
individual adherence to antiretroviral therapy, the effective
control of medical practitioner/researchers over access to
research subjects is highly problematic. There needs to be a
more tolerant and constructive attitude towards social science
research on the part of HIV clinicians who control access to
patients on antiretroviral therapy.
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ERRATUM
There was an error in the article entitled ‘Staging of HIV disease in children – towards
pragmatism?’, which appeared in the November 2005 issue of the Journal (issue 21). In Table II
(p. 16), hepatosplenomegaly should have been listed as a stage 2 and not a stage 1 event.
